Streetbeat News

Revenues

SNDA

Sonida Senior Living (NYSE:SNDA) reported Q2 EPS of $(0.86), a significant improvement from $(2.11) YoY. Sales increased by 11.70% to $70.21M from $62.85M YoY.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 12:24 pm

TKLF

Yoshitsu Co., Ltd (NASDAQ:TKLF) has entered into agreements with Grun Group Thailand Co. Ltd. to establish a franchise network in Southeast Asia under the 'Tokyo Lifestyle' brand. This move is part of Yoshitsu's regional expansion strategy.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 12:15 pm

FTRE

Fortrea Holdings shares are trading lower after the company reported worse-than-expected Q2 financial results and cut its FY24 revenue guidance below estimates.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 12:14 pm

MTEK

Maris-Tech announced preliminary gross revenues of $3M-$3.4M for the first half of 2024, reflecting a significant year-over-year increase of 630-720%.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 12:14 pm

NKLA

Nikola Corporation is continuing to deliver HYLA refueling solutions to support the ramp-up of Class 8 hydrogen fuel cell electric trucks in Southern California along the 5 Freeway.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 12:06 pm

MSTR

MicroStrategy shares fell by 3.10% in pre-market trading, reflecting Bitcoin's performance near $58,000. The company's strong association with Bitcoin has led to significant stock returns but also exposes it to cryptocurrency market volatility.

Portfolio Pulse from Benzinga Neuro

August 12, 2024 | 12:05 pm

PXS

Pyxis Tankers (NASDAQ:PXS) reported Q2 2024 earnings of $0.43 per share and sales of $13.910 million, beating the analyst consensus estimate of $13.290 million. This represents a 46.34% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 12:03 pm

YMAB

Y-mAbs Therapeutics shares are trading lower after the company reported worse-than-expected Q2 financial results and issued FY24 total net revenue guidance with its midpoint below estimates.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 12:01 pm

CLDX

7 analysts have shared their evaluations of Celldex Therapeutics (NASDAQ:CLDX) over the past three months, with a mix of bullish and somewhat bullish ratings. The average 12-month price target is $76.29. The company has shown significant revenue growth but faces challenges with net margins.

Portfolio Pulse from Benzinga Insights

August 12, 2024 | 12:01 pm

PPC

Analysts' ratings for Pilgrims Pride (NASDAQ:PPC) over the last quarter show a mix of bullish to bearish sentiments. The average 12-month price target has increased by 6.46% to $44.0. Key analysts have raised their price targets, reflecting positive market conditions and company performance. Pilgrims Pride has shown strong financial metrics, including a 5.83% revenue growth rate, a 7.16% net margin, and a 9.05% ROE.

Portfolio Pulse from Benzinga Insights

August 12, 2024 | 12:00 pm